National Jewish Health and Ceragenix Pharmaceuticals, Inc. Announce Compound Shows Promise for Treating Potentially Lethal Viral Infections

Published: Jun 22, 2009

DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc.(“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that researchers at National Jewish Health, led by Dr. Donald Y. Leung and Dr. Michael Howell, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments and preclinical animal testing that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat viral infections from the vaccinia virus. The research appears ahead of print in an advanced online publication of the Journal of Investigate Dermatology, the official journal of the Society for Investigative Dermatology. This work was funded by the National Institute of Allergy and Infectious Diseases Atopic Dermatitis Vaccinia Network.

Back to news